Next Article in Journal
Stemarane Diterpenes and Diterpenoids
Next Article in Special Issue
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
Previous Article in Journal
Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes
Previous Article in Special Issue
Core-Fucosylated Tetra-Antennary N-Glycan Containing A Single N-Acetyllactosamine Branch Is Associated with Poor Survival Outcome in Breast Cancer
Open AccessReview

Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy

Division of Medical Oncology, University of Colorado School of Medicine, Genitourinary Cancer Program, MS 8117, 12801 E. 17th Ave, Room L18-8119, Aurora, CO 80045, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(11), 2626; https://doi.org/10.3390/ijms20112626
Received: 12 May 2019 / Revised: 24 May 2019 / Accepted: 27 May 2019 / Published: 28 May 2019
Prostate cancer (PCa) is the most common cancer in men, and more than 10% of men will be diagnosed with PCa during their lifetime. Patients that are not cured with surgery or radiation are largely treated with endocrine therapies that target androgens or the androgen receptor (AR), a major driver of PCa. In response to androgen deprivation, most PCas progress to castrate resistant PCa, which is treated with anti-androgens like enzalutamide, but tumors still progress and become incurable. Thus, there is a critical need to identify cellular pathways that allow tumors to escape anti-androgen therapies. Epidemiological studies suggest that high-fat diets play important roles in PCa progression. Lipid metabolism rewires the PCa metabolome to support growth and resistance to endocrine therapies, although the exact mechanisms remain obscure. Therapeutic effects have been observed inhibiting several aspects of PCa lipid metabolism: Synthesis, uptake, and oxidation. Since AR remains a driver of PCa in advanced disease, strategies targeting both lipid metabolism and AR are starting to emerge, providing new opportunities to re-sensitize tumors to endocrine therapies with lipid metabolic approaches. View Full-Text
Keywords: lipid synthesis; lipid oxidation; AR; prostate cancer; CPT1A; FASN; endocrine resistance; anti-androgens; dietary lipids; combination therapy lipid synthesis; lipid oxidation; AR; prostate cancer; CPT1A; FASN; endocrine resistance; anti-androgens; dietary lipids; combination therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Stoykova, G.E.; Schlaepfer, I.R. Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. Int. J. Mol. Sci. 2019, 20, 2626.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop